ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.71 USD
+0.40 (2.45%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $16.71 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACAD 16.71 +0.40(2.45%)
Will ACAD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Other News for ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting